Table 1 Clinical and biological features of CLL patients enrolled in the study.

From: Revisiting the role of interleukin-8 in chronic lymphocytic leukemia

CLL patient #	Gender	Age (years)	Binet	Lymphocytes (×10⁹/L)	CD19⁺ %*	CD38⁺ %^Δ	CD49d⁺ %^λ	IGHV mutational status	Experiments performed
1	Male	61	C	30.4	82	79	83	n.d.	CXCR1/2; Survival
2	Female	81	A	56.7	93	6	7	M	CXCR1/2; IL8 production^I
3	Male	84	A	29.4	81	2	6	M	CXCR1/2; IL8 production^I
4	Male	74	B	129	97	3	40	n.d.	CXCR1/2
5	Female	69	A	14.1	86	1	9	M	CXCR1/2
6	Male	65	B	67.5	96	37	4	U	CXCR1/2; IL8 production^I
7	Female	65	C	243	97	86	56	M	CXCR1/2
8	Female	70	B	90.9	97	0.5	2	M	CXCR1/2; Survival
9	Female	75	C	179	97	0.2	99	M	CXCR1/2; IL8 production^I
10	Male	69	C	61.1	93	91	5	M	CXCR1/2; Survival
11	Male	84	B	31.2	95	6	1	M	CXCR1/2; IL8 production^{I E}; Survival
12	Male	82	A	25.5	95	0.6	2	M	CXCR1/2; IL8 production^I
13	Male	60	B	6.90	85	2	31	M	CXCR1/2
14	Female	72	C	65.0	87	16	0.4	n.d.	CXCR1/2
15	Female	64	A	16.9	69	2	8	n.d.	CXCR1/2
16	Male	61	C	58.0	84	0.1	1	M	CXCR1/2
17	Male	76	A	24.8	57	8	1	M	CXCR1/2; IL8 production^{I E}; Survival
18	Male	80	B	104	95	98	26	n.d.	CXCR1/2; Survival
19	Female	70	A	45.0	88	1	1	n.d.	CXCR1/2
20	Male	71	A	27.7	89	0.3	2	n.d.	CXCR1/2
21	Male	72	A	54.0	88	0.8	3	M	CXCR1/2
22	Male	64	A	12.3	75	1	n.d	M	CXCR1/2; IL8 production^{I E}
23	Female	82	A	11.1	78	39	40	n.d.	CXCR1/2
24	Male	62	C	2.10	23	3	22	U	CXCR1/2
25	Male	70	A	57.0	90	20	n.d	n.d.	CXCR1/2; IL8 production^{I E}
26	Male	69	B	30.0	71	9	n.d	M	CXCR1/2; IL8 production^E
27	Female	45	C	57.2	94	67	4	U	CXCR1/2; IL8 production^I
28	Male	57	B	20.5	85	0.1	0.2	n.d.	CXCR1/2
29	Male	85	B	38.3	91	0.5	n.d	n.d.	CXCR1/2; IL8 production^{I E}
30	Male	71	B	535	98	15	95	U	CXCR1/2; IL8 production ^E
31	Male	67	B	60.2	90	93	99	U	CXCR1/2; IL8 production^{I E}
32	Male	68	B	62.3	94	16	0.6	U	CXCR1/2; IL8 production^{I E}
33	Male	73	B	110	85	44	6	M	CXCR1/2; IL8 production^I
34	Female	87	C	26.8	88	3	99	U	CXCR1/2; IL8 production^{I E}
35	Male	82	B	5.80	67	5	93	U	CXCR1/2
36	Male	61	C	345	97	97	99	U	CXCR1/2; IL8 production^{I E}; Survival
37	Female	77	B	32.4	91	1	18	M	CXCR1/2; IL8 production^{I E}
38	Female	72	A	4.00	85	3	9	M	CXCR1/2
39	Female	63	A	33.0	87	0.1	20	M	CXCR1/2; IL8 production^{I E}; Survival
40	Female	58	A	9.94	84	5	5	n.d.	CXCR1/2
41	Male	61	B	9.70	62	58	62	U	CXCR1/2
42	Female	93	C	24.0	90	0.1	0.1	n.d.	CXCR1/2
43	Female	74	B	91.0	95	5	2	n.d.	CXCR1/2
44	Male	72	A	33.1	83	11	96	U	CXCR1/2
45	Female	76	A	4.40	36	63	50	n.d.	CXCR1/2
46	Female	54	A	40.5	94	1	1	M	CXCR1/2
47	Female	77	C	24.2	98	0.5	60	n.d.	CXCR1/2
48	Male	75	A	5.60	46	3	33	M	CXCR1/2
49	Male	48	A	5.90	51	3	7	n.d.	CXCR1/2
50	Female	57	A	9.30	61	4	23	n.d.	CXCR1/2
51	Female	52	A	7.10	78	5	7	M	CXCR1/2
52	Male	52	A	9.30	75	0.7	1	M	CXCR1/2
53	Male	65	A	7.90	59	38	7	n.d.	CXCR1/2
54	Male	80	A	86.0	94	83	84	n.d.	CXCR1/2
55	Female	54	A	12.0	80	1	2	n.d.	CXCR1/2
56	Female	69	B	5.30	50	0.5	47	n.d.	CXCR1/2

*Percentage of CD19⁺ (B cells, more than 99% CLL cells) in peripheral blood lymphocytes. ^ΔPercentage of CD38⁺ cells in CD19⁺ lymphocytes. ^λPercentage of CD49d⁺ cells in CD19⁺ lymphocytes. ^IMeasured by flow cytometry; ^EMeasured by ELISA. IGHV immunoglobulin heavy chain variable region; M, mutated; U, unmutated. n.d., indicates not determined.

Back to article page

Table 1 Clinical and biological features of CLL patients enrolled in the study.

Search

Quick links